Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Amortizatization of Intangibles (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Amortizatization of Intangibles for 3 consecutive years, with -$183000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 263.39% to -$183000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $151000.0, a 57.1% decrease, with the full-year FY2024 number at $438000.0, up 10.89% from a year prior.
  • Amortizatization of Intangibles was -$183000.0 for Q3 2025 at Mereo BioPharma, down from $118000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $126000.0 in Q3 2023 to a low of -$183000.0 in Q3 2025.
  • A 3-year average of $79454.5 and a median of $112000.0 in 2024 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: surged 358.33% in 2024, then tumbled 263.39% in 2025.
  • Mereo BioPharma's Amortizatization of Intangibles stood at $24000.0 in 2023, then soared by 358.33% to $110000.0 in 2024, then crashed by 266.36% to -$183000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Amortizatization of Intangibles are -$183000.0 (Q3 2025), $118000.0 (Q2 2025), and $106000.0 (Q1 2025).